Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Links to access the corporate update presentation and the panel discussion will be posted to Oculis' website on the Events & Presentation page under the Investors & Media section.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis' highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
[email protected]
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Opendoor stock pops 10% as company says CEO will step down
Opendoor Technologies (OPEN) shares spiked as 8% in early trading Friday after the company announced that CEO Carrie Wheeler will step down, effective immediately. The company's board appointed Opendoor's chief technology and product officer Shrisha Radhakrishna as president and interim leader of the company. Opendoor, which uses iBuyer real estate technology to flip homes, said it was searching for a new CEO. Since going public through a SPAC transaction in 2020, Opendoor has yet to post a profitable quarter. The company received a warning in May that it faced potential delisting from the Nasdaq after trading under $1 for more than 30 days. Shares have surged more than 200% in the past month, powered in part by Carvana (CVNA) turnaround spotter EMJ Capital and speculative investors on Reddit's wallstreetbets, a haven for meme stocks. EMJ Capital founder and president Eric Jackson said in an X post on July 14 that his firm was taking a long position in Opendoor, which was then trading under $1 per share. "The communication on the earnings call from the CEO and the CFO was really awful," Jackson told Yahoo Finance last week. Jackson has been critical of Opendoor's top leadership, most recently following the company's latest quarterly results in early August, when the stock sank 20% following disappointing earnings forecast. Year-to-date Opendoor shares are up 100%. Sign in to access your portfolio
Yahoo
7 minutes ago
- Yahoo
UK patients rush for obesity jab before Eli Lilly raises price 170% to appease Donald Trump
Patients are racing to secure the weight loss drug Mounjaro ahead of a price rise of up to 170 per cent in the UK, as drugmaker Eli Lilly
Yahoo
7 minutes ago
- Yahoo
StanChart shares fall 7% after U.S. lawmaker calls for probe
LONDON (Reuters) -Shares in Standard Chartered fell 7% on Friday after a U.S. Republican lawmaker wrote to the Attorney General Pam Bondi asking for action to be taken against the bank over alleged "ongoing sanctions evasion". Elise Stefanik, a New York Republican, requested in a letter shared on the X social media platform and published on her website that a special attorney be appointed to look into Standard Chartered's alleged failings. Standard Chartered did not immediately respond to a request for comment. The bank's shares, which had been about 1.5% lower earlier on Friday, plunged and were last down 7% at 1433 GMT. One trader linked the share move to the letter. Like other European lenders, Standard Chartered's stock has risen sharply this year and hit a near 12-year high earlier this week.
